Mestag Therapeutics

Mestag Therapeutics is a fast-moving biotech, formed to explore emerging understanding of fibroblast subpopulations as targetable drivers of disease.

[Mestag Therapeutics @Mestagtx]

Honored to welcome back Suzie Smith, a #bowelcancer warrior who's turning her journey into a mission to help others. 💙

Read her story: https://t.co/hDB8ah5HjQ

[Mestag Therapeutics @Mestagtx]

Our CEO, Susan Hill and CMO, Lindsey Rolfe will be at #ASCO26 in Chicago, May 29–June 2, following the initiation of our Phase I #STARLYS trial.

Connect to learn how Mestag is advancing fibroblast immunology in solid tumors.

[Mestag Therapeutics @Mestagtx]

📢First patient dosed.

MST‑0312 enters the clinic in a first-in-human Phase I STARLYS trial in patients with selected advanced tumors.

🔗https://t.co/Ovoc4zRQ0Y

[Mestag Therapeutics @Mestagtx]

Next week at #BioEquityEurope

Our CEO Susan Hill will join the panel “Compressing Time: How Can Europe Win on Speed and Efficiency?” to discuss Europe’s competitiveness in global biotech.

Details below 👇

[Mestag Therapeutics @Mestagtx]

Today marks International Day of Immunology.

At @MestagTx, we’re advancing new therapeutics for cancer and inflammatory disease by harnessing fibroblast immunology to help restore immune function.

https://t.co/K8i74sNI3Y

[Mestag Therapeutics @Mestagtx]

Join @Mestagtx at the Anglonordic Life Science Conference in London on 23 April.

Hear from our CEO, Susan Hill as she showcases the pioneering science behind our therapeutic pipeline in oncology and inflammatory disease.

⏰ 10:30 - 11.45am
📍 Biotech Room 1

#Anglonordic2026

[Mestag Therapeutics @Mestagtx]

📢 We’ll be presenting a late‑breaking poster at the AACR Annual Meeting 2026, showcasing preclinical findings from #MST‑0312, our FAP‑LTBR bispecific antibody program.

⏰ 9:00 a.m.–12:00 p.m. | April 21
📌 Poster Section 53

👉 https://t.co/6o6udJWNTs

#AACR2026 #Oncology

[Mestag Therapeutics @Mestagtx]

An encouraging read in @businessweekly, highlighting a strong Q1 for Cambridge-based life sciences companies, with $265m raised!
We are proud to be a part of such a dynamic and innovative life sciences ecosystem.
👉https://t.co/nh9pQlaDlK

[Mestag Therapeutics @Mestagtx]

Big news: we’ve closed a $40 million financing and strengthened our leadership team with Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer.

Read the full press release here: https://t.co/5kDpCZu9Cn

[Mestag Therapeutics @Mestagtx]

At the Cancer Immunotherapy Keystone Symposia on March 16th, visit our poster to hear the latest updates on targeted LTBR agonist MST-0312, designed to induce TLS and HEV in tumors. Poster details: https://t.co/eebX6q6xiC

[Mestag Therapeutics @Mestagtx]

TeamMestag is excited to participate in #AACRIO26, a leading forum directing the immune system to the treatment of cancer. MST-0312 is designed to induce TLS in tumors, driving immune cell access and education. To learn more about our upcoming STARLYS trial, reach out to us.

[Mestag Therapeutics @Mestagtx]

Today, we celebrate the women across our company whose intellect and curiosity shape our science and culture. We’re proud of our inclusive team, as diversity drives better science and patient outcomes, and role models for our future scientific leaders matter.

[Mestag Therapeutics @Mestagtx]

Our CBO Robert de Jonge will be participating in a panel discussion titled “Successful Valorisation of Bio-Innovation,” sharing insights on building biotech companies across the Belgian and UK biotech ecosystems.

[Mestag Therapeutics @Mestagtx]

Proud to support the UK BioIndustry Association (BIA), a driving force behind the UK’s world-class life sciences sector -- backing innovation, shaping policy & attracting investment to turn breakthrough science into medicines for patients. Looking forward to the #BIAGalaDinner.

[Mestag Therapeutics @Mestagtx]

2026 is an important year as we advance our ground-breaking FAP-LTBR bispecific, designed to induce tertiary lymphoid structures in tumors, into clinic. Join us in SF at the ASCO GI Symposium or JP Morgan Healthcare Conference by reaching out via: https://t.co/f4cA0Rs4FE

[Mestag Therapeutics @Mestagtx]

Our CEO Susan Hill joins a distinguished panel at #BostonCEO to share insights on BD, shaped by years of leading strategy and operations in the C-suite across multiple life sciences companies, and hands-on BD experience in big biotech and pharma.

[Mestag Therapeutics @Mestagtx]

At #ESMO2025, we are discussing our M300 program (entering the clinic in 2026) and the role of TLS induction in solid tumors. TLS is strongly correlated with survival across cancers -- pointing to a powerful new therapeutic class. Looking forward to connecting there!

[Mestag Therapeutics @Mestagtx]

At #BioCenturyGrandRounds, we are excited to showcase how we are translating powerful biology into patient impact as we prepare for our first anti-cancer drug candidate, LTBRxFAP bispecific antibody, to enter the clinic in 2026.

[Mestag Therapeutics @Mestagtx]

Join us at #CICON25 for a presentation on our targeted LTBR agonist antibody program, M300, which is entering the clinic early next year. M300has been shown to induce TLS & HEV in solid tumors, leading to potent anti-tumor responses in preclinical models.

[Mestag Therapeutics @Mestagtx]

We proudly support 2 employee-chosen charities each year. This year, we welcomed Serga Collett from Scleroderma & Raynaud’s UK (SRUK), who shared her inspiring story at our Annual Sports Day. From Egg & Spoon to Flickin’ Chickins, it was a day full of fun, community, and purpose!